Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer
Status:
Unknown status
Trial end date:
2018-12-30
Target enrollment:
Participant gender:
Summary
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion
criteria are consist of non-metastatic esophageal cancer who are going to receive
chemo-radiotherapy. Sample size is 100 people (50 people in each group). In the intervention
group, patients are going to inject an enoxaparin (40 mg) daily concurrent by
chemo-radiation. Therefore patients with esophageal cancer are going to assign randomly to
control group (only chemo-radiotherapy) and intervention group
(chemo-radiotherapy+enoxaparin) using 1:1 allocation. Four to 6 weeks after treatment, all
patients undergo upper GI endoscopy and then esophagectomy. Endoscopic and pathological
findings (after esophagectomy) are considered as clinical and pathological response,
respectively.